Publications by authors named "Ai-Jun Ouyang"
Article Synopsis
- Benign prostatic hyperplasia (BPH) is a prevalent condition in older adults, marked by excessive growth of prostate cells, and neferine—an alkaloid with antioxidant and anti-inflammatory properties—shows promise in treating it.
- Neferine administration in a BPH mouse model reduced prostate weight and expression levels of various proteins linked to BPH progression, potentially indicating its effectiveness in managing the disease.
- Additionally, neferine appears to counteract the effects of TGF-β1 on prostate cells, suggesting its role in regulating important signaling pathways that contribute to prostate health, making it a potential candidate for BPH treatment.
Introduction: Prostate cancer is the second-leading cause of cancer death in men. Sinularin is a soft coralsderived natural compound that has anticancer activity in many cancer cells. However, the pharmacological action of sinularin in prostate cancer is unclear.
View Article and Find Full Text PDF6-Gingerol is a bioactive compound isolated from . 6-Gingerol has been shown to have anticancer effects in numerous types of cancer cell. The mechanisms underlying the anticancer effect of 6-Gingerol in prostate cancer requires investigation.
View Article and Find Full Text PDFmicroRNA, a family of small non-coding RNA, plays significant roles in regulating gene expression, mainly via binding to the 3'-untranslated region of target genes. Although the role of miRNA in regulating neuroinflammation via the innate immune pathway has been studied, its role in the production of inflammatory mediators during microglial activation is poorly understood. In this study, we investigated the effect of miR-27a on lipopolysaccharide (LPS)-induced microglial inflammation.
View Article and Find Full Text PDFArticle Synopsis
- Ongoing research indicates a potential safety concern with digoxin in atrial fibrillation (AF) patients due to an observed increased risk of mortality.
- Eleven observational studies were analyzed, involving over 318,000 patients followed for an average of 2.8 years, revealing a 21% increased risk of death linked to digoxin use.
- The findings suggest that this increased risk exists for both AF patients with and without heart failure, highlighting the need for further extensive randomized trials to better understand digoxin's effects.